Katrina J. Church net worth and biography

Katrina Church Biography and Net Worth

SVP of Bioventus

Katrina Church is the Chief Compliance Officer of Bioventus and is responsible for all ethics and compliance functions at the company.

Prior to joining Bioventus, Katrina spent nearly 11 years with the Merz Group of companies where she served in several corporate counsel and compliance roles, most recently as Global Compliance Officer for Merz Pharma GmbH & Co KGaA. In 2020, Church was nominated for several industry awards for compliance training, and won the 2020 Women in Compliance Award for “Most Impactful Compliance Training Programme of the Year.”

Previously, she was Executive Vice President and General Counsel of Connetics Corporation, a medical dermatology company that was acquired by Stiefel in 2008. Prior to her career with Stiefel, she served as general counsel of VISX, Inc., a medical device company that pioneered the vision treatment known as LASIK. She began her career as an attorney at Hopkins & Carley, a San Jose-based law firm.

Katrina received her Juris Doctor from New York University School of Law and an AB magna cum laude from Duke University.

What is Katrina J. Church's net worth?: The estimated net worth of Katrina J. Church is at least $452.89 thousand as of March 17th, 2025. Church owns 52,540 shares of Bioventus stock worth more than $452,895 as of March 13th. This net worth estimate does not reflect any other investments that Church may own. Learn More about Katrina J. Church's net worth.
How do I contact Katrina J. Church?: The corporate mailing address for Church and other Bioventus executives is 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703. Bioventus can also be reached via phone at (919) 474-6700 and via email at [email protected]. Learn More on Katrina J. Church's contact information.
Has Katrina J. Church been buying or selling shares of Bioventus?: Katrina J. Church has not been actively trading shares of Bioventus in the last ninety days. Most recently, Katrina J. Church sold 1,018 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $9.75, for a transaction totalling $9,925.50. Following the completion of the sale, the senior vice president now directly owns 52,540 shares of the company's stock, valued at $512,265. Learn More on Katrina J. Church's trading history.
Who are Bioventus' active insiders?: Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.
Are insiders buying or selling shares of Bioventus?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.
Information on this page was last updated on 3/11/2026.

Katrina J. Church Insider Trading History at Bioventus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2025	Sell	1,018	$9.75	$9,925.50	52,540
12/23/2024	Sell	2,535	$10.53	$26,693.55	47,264
7/3/2023	Sell	394	$2.83	$1,115.02	11,828
4/3/2023	Sell	117	$1.07	$125.19	10,353
4/1/2023	Sell	15	$14.07	$211.05	10,338
2/11/2021	Buy	2,500	$13.00	$32,500.00	2,500

Katrina J. Church Buying and Selling Activity at Bioventus

Bioventus Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.62

$8.56

$8.79

50 Day Range

MA: $8.25

$7.57

$9.10

2 Week Range

Now: $8.62

$5.81

$10.13

Volume

286,351 shs

Average Volume

334,578 shs

Market Capitalization

$716.75 million

P/E Ratio

26.12

Dividend Yield

N/A

Beta

0.78